Summary
The reproductive hormone, estrogen, contributes to the development of breast cancer by binding to the estrogen receptor (ER) in the nucleus, triggering cell growth and tumor promotion. In addition to its role in regulating target genes and signaling pathways involved in cell cycle progression, the ER-signaling pathway may regulate the expression of chromatin-remodeling gene, Metastasis-associated 3 (MTA3), or interact with chromatin-remodeling protein, Metastasis-associated 1 (MTA1). The invasion-suppressor gene, E-Cadherin (E-Cad), has recently been identified as a downstream target gene regulated by the ER-MTA3 pathway via the transcriptional repressor, Snail, and the ER-MTA3-Snail-E-Cad pathway has therefore been evoked to explain the clinical observation that ER expression in breast cancer is generally associated with a better clinical outcome. Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case–control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways. Support for this hypothesis came from the observations that (a)␣with the exception of Snail, which interacted differently with reproductive risk factors in relation to breast cancer risk, there was a joint effect of the SNPs of these genes and estrogen-related risk factors (age at first full-term pregnancy and obesity, measured by the body mass index) on breast cancer risk (p < 0.05); (b) a trend toward increased risk of developing breast cancer was seen in women harboring a greater number of putative high-risk genotypes of these genes in ER-signaling pathways; (c) this association between risk and the number of putative high-risk genotypes was stronger and more significant in women thought to have experienced higher estrogen level, i.e., obese women; and (d) the risk effect conferred by obesity was only significant in women with a higher number of putative high-risk genotypes of the ER-signaling genes. These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.
Article PDF
Similar content being viewed by others
References
Hulka B.S., Stark A.T. (1995). Breast cancer: cause and prevention. Lancet 346:883–887
Kelsey J.L., Gammon M.D., John E.M. (1993). Reproductive factors and breast cancer. Epidemiol. Rev. 15:36–47
Pike M.C., Spicer D.V., Dahmoush L., Press M.F. (1993). Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:17–35
Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. (2002). Production and actions of estrogens. N. Engl. J. Med. 346:340–352
Dickson R.B., Stancel G.M. (2000). Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. 27:135–145
Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., Katzenellenbogen B.S. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574
Fujita N., Kajita M., Taysavang P., Wade P.A. (2004). Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol. Endocrinol. 18:2937–2949
Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S., Wade P.A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 113:207–219
Kumar R., Wang R.A., Bagheri-Yarmand R. (2003). Emerging roles of MTA family members in human cancers. Semin. Oncol. 30 (5 Suppl 16):30–37
Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2:84–89
Fearon E.R. (2003). Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer. Cancer Cell 3:307–310
Kumar R. (2003). Another tie that binds the MTA family to breast cancer. Cell 113:142–143
Ding S.L., Sheu L.F., Yu J.C., Yang Y.L., Chen B., Leu F.J., Shen C.Y. (2004). Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J. Biomed. Sci. 11:911–919
Gold B., Kalush F., Bergeron J., Scott K., Mitra N., Wilson K., Ellis N., Huang H., Chen M., Lippert R., Halldorsson B.V., Woodworth B., White T., Clark A.G., Parl F.F., Broder S., Dean M., Offit K. (2004). Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 64:8891–8900
Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., Huang C.S., Lung J.C., Wu C.W. (2000). Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma- an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60:3884–3892
Cheng C.W., Wu P.E., Yu J.C., Huang C.S., Yue C.T., Wu C.W., Shen C.Y. (2001). Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20:3814–3823
Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. (1998). E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405
Kumar R., Wang R.A., Mazumdar A., Talukder A.H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C.J., Vadlamudi R.K. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418:654–657
Yang P.S., Yang T.L., Liu C.L., Wu C.W., Shen C.Y. (1997). A case–control study of breast cancer in Taiwan. Br. J. Cancer 75:752–756
Lo Y.L., Yu J.C., Huang C.S., Tseng S.L., Chang T.M., Chang K.J., Wu C.W., Shen C.Y. (1998). Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int. J. Cancer 79:580–587
Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. (1999). Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:4870–4875
Cheng T.C., Chen S.T., Huang C.S., Fu Y.P., Yu J.C., Cheng C.W., Wu P.E., Shen C.Y. (2005). Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int. J. Cancer 113:345–353
Lung J.C., Chu J.S., Yu J.C., Yue C.T., Lo Y.L., Shen C.Y., Wu C.W. (2002). Aberrant expression of cell cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Gene Chromosom Cancer 34:276–284
Fu Y.P., Yu J.C., Cheng T.C., Lou M.A., Hsu G.C., Wu C.Y., Chen S.T., Wu H.S., Wu P.E., Shen C.Y. (2003). Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63:2440–2446
Lo Y.L., Yu J.C., Chen S.T., Yang H.C., Fann C.S., Mau Y.C., Shen C.Y. (2005). Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int. J. Cancer 115:276–283
Li L.C., Chui R.M., Sasaki M., Nakajima K., Perinchery G., Au H.C., Nojima D., Carroll P., Dahiya R. (2000). A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 60:873–876
Shin Y., Kim I.J., Kang H.C., Park J.H., Park H.W., Jang S.G., Lee M.R., Jeong S.Y., Chang H.J., Ku J.L., Park J.G. (2004). A functional polymorphism (−347 G–>GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis 25:2173–2176
Ohnishi Y., Tanaka T., Ozaki K., Yamada R., Suzuki H., Nakamura Y. (2001). A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46:471–477
Sellers T.A. (2004). Genetic Ancestry and Molecular Epidemiology. Cancer Epidemiol. Biomarkers Prev. 13:499–500
Kleinbaum DG, Kupper LL, Morgenstern KH. Epidemiologic Research : Principles and Quantitative Methods. Van Nostrand Reinhold NY, 1982
Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. PWS-KENT Publishing Company Boston, 1998
Vineis P. (2004). Individual susceptibility to carcinogens. Oncogene 23:6477–6483
Russo J., Tay L.K., Russo I.H. (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat. 2:5–73
Johnston S.R., Dowsett M. (2003). Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3:821–831
Smith I.E., Dowsett M. (2003). Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348:2431–2442
Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99:2884–2889
Roberts C.W., Orkin S.H. (2004). The SWI/SNF complex-chromatin and cancer. Nat. Rev. Cancer 4:133–142
Versteege I., Sevenet N., Lange J., Rousseau-Merck M.F., Ambros P., Handgretinger R., Aurias A., Delattre O. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203–206
Gunduz E., Gunduz M., Ouchida M., Nagatsuka H., Beder L., Tsujigiwa H., Fukushima K., Nishizaki K., Shimizu K., Nagai N. (2005). Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int. J. Oncol. 26:201–210
Medina P.P., Carretero J., Fraga M.F., Esteller M., Sidransky D., Sanchez-Cespedes M. (2004). Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 41:170–177
Bau D.T., Fu Y.P., Chen S.T., Cheng T.C., Yu J.C., Wu P.E., Shen C.Y. (2004). Breast cancer risk and the DNA double-strand break end-joining capacity of non-homologous end-joining genes are affected by BRCA1. Cancer Res 64:5013–5019
Hazan R.B., Qiao R., Keren R., Badano I., Suyama K. (2004). Cadherin switch in tumor progression. Ann. NY Acad. Sci. 1014:155–163
Hatsell S., Rowlands T., Hiremath M., Cowin P. (2003). Beta-catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 8:145–158
Guilford P. (1999). E-cadherin downregulation in cancer: fuel on the fire? Mol. Med. Today 5:172–177
Okubo T., Truong T.K., Yu B., Itoh T., Zhao J., Grube B., Zhou D., Chen S. (2001). Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res. 61:1338–1346
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, JC., Hsu, HM., Chen, ST. et al. Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility. J Biomed Sci 13, 419–432 (2006). https://doi.org/10.1007/s11373-006-9069-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11373-006-9069-7